



Date: 27 April 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office
and

Operational Office:

Suite 3, Level 4

828 Pacific Highway

Gordon NSW 2072

Australia

Board of Directors

Mr Peter Marks

Chairman

Non-Executive

Director

Dr Graham Kelly

Chief Executive Officer

Managing Director

Dr Ian Dixon

Non-Executive

Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOXOPHARM CEO DISCUSSES NOX66 RADIOTHERAPY CLINICAL PROGRAMS

Sydney, 27 April 2018: Noxopharm (ASX: NOX) CEO, Dr Graham Kelly, discusses with Finance News Network the Company's 2 current radiotherapy studies being conducted in men with late-stage prostate cancer. These are studies of a combination of NOX66 with:

- Internally-delivered radiotherapy (LUPIN study) being conducted at St Vincent's Hospital, Sydney, and
- externally-delivered radiotherapy being conducted at multiple sites in the multi-national DARRT-1 study.

To hear the interview, please visit the following link;

<https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1228>

About LUPIN

LUPIN is ¹⁷⁷LuPSMA-617 in Combination with NOX66 Study. The study design is a prospective, open label, non-randomised Phase 1 pilot study involving 2 different dosages of NOX66 (400 and 800 mg) in 16 men with metastatic castrate-resistant prostate cancer that is PSMA-positive. ¹⁷⁷LuPSMA-617 is administered in up to six 1x monthly cycles, each cycle comprising a single intravenous injection of ¹⁷⁷LuPSMA followed by 10 days of NOX66 treatment. Patients are examined for tumour response using ⁶⁸gallium-PSMA-617 after cycle 3 and then at 12 months. Efficacy outcomes are serum PSA levels, tumour load (imaging), quality of life, pain scores, time to disease progression, progression-free survival and overall survival. LUPIN is an investigator-initiated study for which Noxopharm is providing financial support. The Principal Investigators are A/Prof Anthony Joshua and A/Prof Louise Emmett.

About DARRT Program

DARRT is Direct and Abscopal Response to Radiotherapy. It relates to the use of NOX66 to enhance the known abilities of radiotherapy both to kill cancer cells directly exposed to radiation (direct response), and to result in the death of cancer cells outside of the field of radiation (abscopal response). DARRT-1 is a prospective, open label, non-randomised Phase

1 pilot study involving 24 men with metastatic castrate-resistant prostate cancer and with measurable disease. Treatment is a palliative dosage of radiotherapy delivered by external beam radiotherapy to 1-2 individual lesions in 5 fractionated doses. NOX66 is administered daily for the duration of the radiotherapy treatment + 7 days. Three dosages of NOX66 are being used – 400, 800 and 1200 mg. Patients are scanned at + 6 and + 12 weeks.

About late-stage prostate cancer

The number of men estimated in 2018 to die from prostate cancer is 3,500 in Australia and 27,000 in the US. Globally, prostate cancer is the second most common cause of cancer-related deaths in men after lung cancer. Standard treatments of prostate cancer include surgery (prostatectomy), radiotherapy, chemotherapy and hormone (anti-androgen) therapy. Prostate cancer metastasises mainly to the skeleton and lymph nodes, and to a lesser extent to the lungs, liver and brain. Externally-delivered radiotherapy typically is used on a palliative basis to attempt shrinkage of a small number (1-2) of the larger lesions in order to provide pain relief. However, late-stage prostate cancer typically involves multiple secondary lesions throughout the body, meaning that standard radiotherapy is limited to a small proportion of the lesions.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. The radio-enhancing effects of idronoxil are believed to involve at least 2 functions: (i) its ability to block DNA repair mechanisms (PARP-1, topoisomerases 1 and 2); (ii) its immune-enhancing effects, stimulating the activity of human natural killer (NK) cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

Investor & Corporate Enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.